Skip to main content
Clinical Trials/NCT05733741
NCT05733741
Completed
Phase 4

Preservative-free Topical Anesthetics for the Management of Postoperative Pain Following Photorefractive Keratectomy

Assiut University1 site in 1 country70 target enrollmentJanuary 30, 2023

Overview

Phase
Phase 4
Intervention
Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)
Conditions
Myopia
Sponsor
Assiut University
Enrollment
70
Locations
1
Primary Endpoint
Postoperative pain score on the verbal rating scale (VRS)
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The goal of this interventional comparative study is to assess the efficacy and safety of a novel regimen of preservative-free unit-dose topical anesthetics for controlling early postoperative pain following single-step transepithelial PRK surgery.

The main research questions to answer are:

  • Question 1: Are topical anesthetics effective in reducing post-PRK pain?
  • Question 2: Are short-term topical anesthetics toxic to the cornea?
  • Question 3: How to prevent abuse of topical anesthetics by patients at home?

Participants were planned to undergo a bilateral single-step transepithelial PRK surgery to correct their refractive errors and received a standard post-PRK treatment regimen for both eyes. Additionally, one eye was offered a preservative-free topical anesthetic as an experimental group and the other eye was offered a preservative-free artificial tear as a control group.

Detailed Description

Photorefractive keratectomy (PRK) is a well-established surface ablation procedure for correction of refractive errors which involves the removal of corneal epithelium in a large diameter usually more than 6 mm followed by stromal ablation. Early postoperative pain within the first few days after surgery is one of the commonest complications reported after PRK. The classic postoperative treatment includes the prescription of topical antibiotics and frequent preservative-free lubricants to accelerate epithelial healing. The current treatment regimens also includes topical steroids, topical non-steroidal anti-inflammatory drugs (NSAID) and oral NSAID to reduce inflammation and post-PRK pain. Earlier studies suggested that topical anesthetics in diluted concentrations and fractional doses didn't delay corneal epithelial regeneration after PRK but their use didn't gain popularity because of problems with topical formulation, stability and preservation.

Registry
clinicaltrials.gov
Start Date
January 30, 2023
End Date
April 15, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mahmoud Abdel-Radi

Principal Investigator

Assiut University

Eligibility Criteria

Inclusion Criteria

  • Patients who are candidate for PRK surgery with
  • Myopia up to - 6 diopters or myopic astigmatism up to - 4 diopters.
  • Corneal thinnest pachymetry of 500 µm
  • Residual stromal bed more than 350 µm after epithelial ablation.

Exclusion Criteria

  • Patients with
  • Corneal scars or dry eye disease,
  • Past ocular surgery,
  • History of contact lens wear,
  • Systemic diseases such as diabetes mellitus and autoimmune diseases,
  • History of oral analgesics abuse.

Arms & Interventions

Preservative-free topical anesthetics group

Patients in this group had the standard post-PRK treatment regimen in addition to the prescription of preservative-free topical anesthetics for pain control following single-step transepithelial PRK surgery in one eye.

Intervention: Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)

Preservative-free artificial tears group

Patients in this group had the standard post-PRK treatment regimen in addition to the prescription of preservative-free artificial tears as a placebo following single-step transepithelial PRK surgery in the other eye.

Intervention: Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt).

Outcomes

Primary Outcomes

Postoperative pain score on the verbal rating scale (VRS)

Time Frame: 1 week

The doctor asks the patient to choose the word that best describes his/her pain and then gives it a score from zero to 4 (Zero for no pain, 1 for mild pain, 2 for moderate pain, 3 for severe pain and 4 for unbearable pain).

Postoperative pain score on the visual analogue scale (VAS)

Time Frame: 1 week

The patient is asked to rate his/her pain by choosing a number on a scale from zero to 10 considering zero as no pain and 10 as worst possible pain.

Secondary Outcomes

  • Corneal epithelial healing duration(1 week)
  • Endothelial cell density (ECD)(from preoperative to 1 month postoperative.)

Study Sites (1)

Loading locations...

Similar Trials